Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA; Retina Consultants of Houston, Houston, Texas, USA; Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas, USA.
Department of Ophthalmology, Triemli Hospital, Zurich, Switzerland; Department of Ophthalmology, Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany.
Am J Ophthalmol. 2018 Jun;190:142-149. doi: 10.1016/j.ajo.2018.03.031. Epub 2018 Mar 28.
To review and summarize evidence in the medical literature regarding the use of pars plana vitrectomy in the management of uveitis.
Systematic literature review.
A systematic literature search was conducted for relevant articles on pars plana vitrectomy for the management of uveitis. Results from the studies were compiled and analyzed.
Thirty-four articles, published from 2005 through 2014, were included in the final data analysis. Thirty-two manuscripts were from retrospective case series and 2 manuscripts were from randomized pilot studies. The median Scottish Intercollegiate Guidelines Network level of evidence grade was 3 and the median Oxford Center for Evidence-based Medicine level of evidence grade was 4. Fewer than 50% of the articles in the current study applied Standardization of Uveitis Nomenclature (SUN) criteria in regard to reporting the anatomic location of uveitis, fewer than 25% of studies applied SUN criteria in regard to the reporting of anterior chamber cells before and after PPV, fewer than 10% of studies applied SUN criteria to the grading of anterior chamber flare before and after PPV, and fewer than 10% of studies applied standardized criteria to the grading of vitreous haze after PPV. Overall, 627 patients and 708 total eyes undergoing PPV for uveitis were included. The average reported age of all patients was 43.4 years. The median duration of uveitis prior to PPV reported in the studies was 36.1 months (range 4-198 months). The median follow-up after PPV reported in the studies was 18.9 months (range 2-114 months). Vision was reported for 519 eyes and was improved in 356 eyes (69%), unchanged in 95 eyes (18%), and worse in 68 eyes (13%) following PPV. Preoperatively, 157 of 300 (52%) eyes in these studies had documented cystoid macular edema compared to 112 of 300 (37%) postoperatively. Median use of oral corticosteroids improved from 48% preoperatively to 12% postoperatively among the reporting studies. Median use of other immunosuppressive medications decreased from 56% preoperatively to 36% postoperatively among the reporting studies.
Although nearly all studies continue to report favorable outcomes of PPV in the management of uveitis, the quality of data remains limited by a lack of application of standardized reporting outcomes, limitations in study design, and a paucity of prospective data.
回顾和总结医学文献中关于使用经睫状体平坦部玻璃体切除术治疗葡萄膜炎的证据。
系统文献回顾。
对经睫状体平坦部玻璃体切除术治疗葡萄膜炎的相关文章进行系统文献检索。对研究结果进行编译和分析。
最终数据分析纳入了 34 篇文章,发表于 2005 年至 2014 年。32 篇论文为回顾性病例系列,2 篇论文为随机试点研究。苏格兰校际指南网络证据等级中位数为 3 级,牛津循证医学中心证据等级中位数为 4 级。当前研究中不到 50%的文章在报告葡萄膜炎的解剖位置时应用了葡萄膜炎命名标准化(SUN)标准,不到 25%的研究在报告经睫状体平坦部玻璃体切除术前和术后前房细胞时应用了 SUN 标准,不到 10%的研究在前房闪辉分级方面应用了 SUN 标准,经睫状体平坦部玻璃体切除术后玻璃体混浊分级也不到 10%的研究应用了标准化标准。总体而言,627 例患者和 708 只眼因葡萄膜炎接受经睫状体平坦部玻璃体切除术治疗。所有患者的平均报告年龄为 43.4 岁。研究中报告的经睫状体平坦部玻璃体切除术前葡萄膜炎的中位持续时间为 36.1 个月(范围为 4-198 个月)。研究中报告的经睫状体平坦部玻璃体切除术后中位随访时间为 18.9 个月(范围为 2-114 个月)。519 只眼报告了视力情况,其中 356 只眼(69%)视力改善,95 只眼(18%)视力不变,68 只眼(13%)视力变差。术前,这些研究中有 157 只/300 只(52%)眼有记录的黄斑囊样水肿,而术后有 112 只/300 只(37%)眼有记录。报告研究中,口服皮质类固醇的中位使用率从术前的 48%降至术后的 12%。报告研究中,其他免疫抑制药物的中位使用率从术前的 56%降至术后的 36%。
尽管几乎所有的研究都继续报告经睫状体平坦部玻璃体切除术治疗葡萄膜炎的良好结果,但由于缺乏标准化报告结果的应用、研究设计的局限性以及前瞻性数据的缺乏,数据质量仍然受到限制。